Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.

中文翻译：

---

加强剂量在增强癌症患者对 COVID-19 疫苗的免疫反应减弱方面的功效。

在一项前瞻性临床试验中评估了癌症患者的抗 COVID-19 免疫动力学。在接种疫苗后 4-6 个月检测到免疫力减弱，在加强剂量后抗尖峰 IgG 滴度显着增加，56% 的血清反应阴性患者在加强疫苗接种后发生血清转化。先前的抗 CD20/BTK 抑制剂治疗与疫苗效力降低有关。